Jorge Cortes, MD
Ponatinib (Iclusig) maintained deep, durable responses in heavily pretreated patients with chronic-phase chronic myeloid leukemia (CP-CML), according to 5-year results from the pivotal PACE trial published in the journal Blood
Overall, the PACE trial included 449 patients who received ponatinib at a starting dose of 45 mg daily. Patients were heavily pretreated, with an estimated 93% and 56% of patients having previously received ≥2 TKIs and ≥3 TKIs, respectively.
... to read the full story